Gilde Healthcare and the other shareholders are selling their entire stake in Definiens AG to MedImmune/AstraZeneca.
Gilde Healthcare is a growth capital firm specialised in the healthcare sector. MedImmune is the global biologics research and development arm of AstraZeneca. The sale marks Gilde’s eighth exit in the past year. An initial consideration of USD 150 million will be paid for all the shares in Definiens, followed by additional predetermined milestone payments.
A team led by lead partner Stefan-Ulrich Müller advised Gilde Healthcare on all aspects of the transaction. Gilde Healthcare was also advised by CMS Hasche Sigle at the time of its investment in Definiens AG in 2012.
Definiens extracts information from tissue samples in digital form, which can then provide new findings for the treatment of cancer.
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over EUR450 million under management.
